CClinicalTrials.gg
CompletedNCT03642730EPISODEUpdated Feb 3, 2021

Interactive Guided Ultrasound Examinations Done by Non-experts of Ultrasound Imaging

An interventional study of TransThoracic Echocardiography imaging in Cardiac Disease, Heart Failure and Cardiac Ischemia, sponsored by Philips Healthcare. Completed at 1 site in France. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-03.

Sponsored by Philips Healthcare · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This prospective study is a pilot study for evaluating a guidance system that aims to facilitate high-quality echocardiographic acquisitions.

Read the detailed description

The primary objective of this study is to assess the feasibility for non-expert users (medical professionals but non-certified sonographers) to acquire parasternal, apical and subcostal views of suitable quality by using an existing ultrasound device (CE-marked, available in the market) and an additional guidance system (software prototype + probe motion tracking device). Such a system will help the user to place the probe on the patient and provide guidance for optimal acquisition of parasternal, apical and subcostal views.

The secondary objective of this study is to assess the feasibility for non-expert users to reproduce a simple clinical protocol by using an existing ultrasound device and the same additional guidance system.

02

Conditions studied

  • Cardiac Disease
  • Heart Failure
  • Cardiac Ischemia

Keywords

  • echocardiography
  • training
  • follow-up
03

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • All volunteers must have the ability to provide informed consent.
  • All volunteers should be affiliated to the French Social Security.
  • All volunteers will be scheduled for a routine transthoracic echocardiography exam in the echocardiography laboratory at the investigation site as part of standard care.

Exclusion criteria

Exclusion Criteria:

  • Subjects with congenital heart diseases (except bicuspid aortic valve)
  • Pregnant women
  • Adults lacking decisional capacity
  • Adults placed under a legal protection regime (guardianship, curatorship, judicial protection)
  • Adults not affiliated to the French Social Security
  • Adults in emergent or critical condition
  • Adults with active pain in the intended scanning region
  • Adults with active skin disease or lesions in the intended scanning region
  • Adults with allergy/sensitivity to ultrasound gel
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Scanned patients

    Scanned patients TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors

    Device: TransThoracic Echocardiography imaging

  • Experimental
    Non-expert scanning volunteers

    Non-expert scanning volunteers (among the medical staff at the clinical site) TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors

    Device: TransThoracic Echocardiography imaging

Interventions

  • DeviceTransThoracic Echocardiography imaging

    ultrasound scanning

05

What researchers measure

Primary outcomes

  1. Echocardiography acquisition score [in %] [Operator's outcome]

    Composite measurement that characterizes the echocardiography acquisition of the operator who is being assessed with respect to a 2D reference acquisition The echocardiography acquisition score is a combination of the view type score and the image quality score

    Time frame: Day 1

  2. Time to acquisition [in seconds] [Operator's performance]

    Time to acquisition \[in seconds\] to reach an echocardiography acquisition score of 25%, 50%, 75% and 90%

    Time frame: Day 1

  3. Displacement [in mm] of the echocardiography probe with respect to the 2D reference acquisition [Technical reproducibility]

    Displacement \[in mm\] of the echocardiography probe at the acquisition time with respect to the 2D reference acquisition \[Reproducibility of the probe position and orientation\]

    Time frame: Day 1

  4. Displacement [in mm] of the echocardiography probe with respect to the ideal acquisition [Geometrical reliability]

    Displacement \[in mm\] of the echocardiography probe at the acquisition time with respect to the ideal (geometrical) acquisition estimated from 3D reference acquisition \[Geometrical reliability of the probe position and orientation\]

    Time frame: Day 1

Secondary outcomes

  1. Left ventricular Ejection Fraction [in %] [Measurement reproducibility]

    Left ventricular Ejection Fraction \[in %\] by Simpson's biplane method

    Time frame: Day 1

06

Study locations

1 site
  • CHU Caen Service de Cardiologie
    Caen, 14033, France
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03642730
Lead sponsor
Philips Healthcare
Responsible party
Sponsor
First posted
Aug 22, 2018
Start date
Dec 1, 2017
Primary completion
Jan 1, 2021
Completion
Jan 1, 2021
Last update
Feb 3, 2021

Study contacts

Eric Saloux, MD
principal investigator · Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion